Columnist Anna Jeter reflects on her mental health needs and various treatment approaches since being diagnosed with PH at ...
Inhibiting GLS1 reduced high blood pressure in the right side of the heart of PAH rats and improved various measures of heart ...
Researchers identified two anoikis-related genes linked with CTEPH, and that may serve as diagnostic biomarkers or treatment ...
In a trial, Gossamer Bio's PAH treatment candidate seralutinib reduced the resistance blood faces moving into the lungs over ...
Tectonic Therapeutic said the findings support the design and population for Phase 2 APEX trial, which will test TX45 in ...
Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...
LungFit PH, a device developed by Beyond Air for administering nitric oxide (NO) therapy, has received marketing approval from the Australian Therapeutic Goods Administration (TGA), which will allow ...
People with pulmonary arterial hypertension (PAH) seen to be at an intermediate risk of death — whether in the low or high range of that middle-level risk — were more likely to have better outcomes ...
The dosing regimen for Winrevair (sotatercept-csrk) is optimal for balancing efficacy and safety in adults with pulmonary arterial hypertension (PAH), an analysis of clinical trial data shows. This ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback